Peptides DB

Research-centric peptide and protocol reference hub

Semaglutide

Research-centric overview

Share
Peptide

Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).

Community effect votes, structured logs, and side-effect summaries.

Effect profile (overview)

Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.

Effect profile (AI + community): Metabolic & appetite 5.0/5 · Skin & aesthetics 3.0/5Healing 0.0Muscle 0.0Metabolic 5.0Neuro 0.0Sleep 0.0Inflammation 0.0Skin 3.0

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

Pain / discomfort0/5
Sleep / recovery+1/5
Performance / output+1/5

Based on 1 anonymized research log. Scroll down for full context and methodology.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

46%reduced appetite
35%early satiety
19%nausea

Research footprint

Last analyzed Apr 17, 2026
7
Studies indexed
0
Human
0
Animal
3
AI analyzed
Evidence mix0% human · 0% animal · 0% cellular · 0% review
Highest phase: Preclinical onlyYears covered: 2026
Librarian pulse — latest actionsFull changelog ↓
  • Apr 17, 12:04 PMRefreshedRefreshed content for Semaglutide
  • Apr 16, 5:14 PMRefreshedRefreshed content for Semaglutide
  • Apr 16, 5:14 PMRefreshedRefreshed content for Semaglutide

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

Refreshed content for Semaglutideai_activityai-researcherApr 17, 2026

Pulled 4 linked studies for context.

No external link
Refreshed content for Semaglutideai_activityai-researcherApr 16, 2026

Pulled 4 linked studies for context. - **content** added: Body content generated (1166 chars).

No external link
Refreshed content for Semaglutideai_activityai-researcherApr 16, 2026

Pulled 4 linked studies for context. - **content** added: Body content generated (1343 chars).

No external link
Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims DataClinical TrialClinicalTrials.govApr 16, 2026

This study emulates the STEP-HFpEF DM heart failure trial using healthcare claims data. It aims to analyze the outcomes associated with semaglutide in patients with heart failure with preserved ejection fraction and diabetes. No specific numeric results or treatment effects are reported in the abstract.

Status: COMPLETED
Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.Clinical TrialClinicalTrials.govApr 16, 2026

This study examines the impact of antiobesity medications on appetite and related hormones and metabolites. The specific medication studied is Semaglutide, although details on the population, dose, and outcomes are not provided in the abstract. The findings regarding appetite modulation and hormonal changes are not explicitly stated.

Status: NOT_YET_RECRUITING
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With PrediabetesClinical TrialClinicalTrials.govApr 16, 2026

This study investigates the pharmacogenetic factors influencing the response to GLP-1 receptor agonists in Mexican-Americans with prediabetes. The specific outcomes measured were not detailed in the abstract. The study is categorized as a Phase 4 trial.

Phase: PHASE4Status: RECRUITING
Pilot Weight Loss Intervention With Dual GIP/GLP-1 Receptor Agonist Therapy in Patients With Endometrial Cancer and Obesity, Overweight, With or Without DiabetesClinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the effects of dual GIP/GLP-1 receptor agonist therapy on weight loss in patients with endometrial cancer and obesity, overweight, with or without diabetes. The specific dose and duration of treatment were not reported in the abstract. The outcomes measured included weight loss and other metabolic parameters.

Phase: EARLY_PHASE1Status: RECRUITING
A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects With Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)Clinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the safety and efficacy of Semaglutide and the fixed-dose combination of Cilofexor and Firsocostat in subjects with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH). The study was randomized, double-blind, and placebo-controlled. Specific numeric outcomes were not reported in the abstract.

Phase: PHASE2Status: COMPLETED
Semantic Scholar search for SemaglutideStudySemanticScholarDec 12, 2025
Tirzepatide vs. Semaglutide: clinical decision-making in the GLP-1 landscape.StudyPubMedDec 12, 2025

Expert opinion on pharmacotherapy · 2025

Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months).StudyPubMedDec 12, 2025

Current medical research and opinion · 2025

GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty.StudyPubMedDec 12, 2025

European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025

Popular stacks

Most commonly stacked peptides based on community research logs.

BPC-157
3x

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Comments appear immediately.

Community research logs (detail)

Showing the latest 1 logs out of 1.

Goal: weight / appetite

Context: sedentary / light • 46-55

Duration ~16.0 weeks • ~1.0 doses/week

Δ scores
Pain +0Sleep +1Perf +1

Weekly GLP-1 agonist with gradual uptitration alongside nutrition coaching. Tracking appetite, weight trend, GI side-effects, and energy levels.

How to read these logs

Each entry is a single, anonymized “n=1” summary with relative change sliders from −5 to +5. Higher positive values indicate perceived improvement; negative values indicate perceived worsening.

Context (training level, age band, duration, and dosing frequency) is shown so you can quickly skim for patterns or outliers. Treat this as qualitative signal layered on top of study data, not as a substitute for controlled trials.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.

Quick tone breakdown of submitted side-effect tags:

PositiveNegativeNeutral / mixed

Top reported tags so far (color reflects tone):

46%reduced appetite
35%early satiety
19%nausea

Librarian Changelog

Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.

22h agoRefreshai-researcher85%

Refreshed content for Semaglutide

1d agoRefreshai-researcher85%

Refreshed content for Semaglutide

1d agoRefreshai-researcher85%

Refreshed content for Semaglutide